Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
News Feb 17, 2009
Vermillion, Inc. has announced that the U.S. Patent Office (USPTO) has issued a notice of allowance to the Company for the discovery of hepcidin as a biomarker for ovarian cancer. The discovery could ultimately lead to the development of an improved, next-generation assay that might provide physicians with additional, valuable information to diagnose ovarian cancer.
"The notice of issuance of this patent validates the strength of our approach in the development of innovative molecular diagnostics," said Eric T. Fung, M.D., Ph.D, Chief Scientific Officer of Vermillion and co-inventor. "This patent comprises an important component of our ovarian cancer patent portfolio."
The patent also covers the measurement of hepcidin by a variety of methods, including mass spectrometry and other immunoassay approaches.
Low Temperatures Turn Stem Cells into Calorie-Burning FatNews
The secret to healthy eating may not be in freezer food, but low temperatures can help turn stem cells into brown fat, a type of fat which helps burn calories. A new study could turn this knowledge into weight-loss treatments.READ MORE
Comments | 0 ADD COMMENT
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018